Neeyan

Neeyan Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation cancer immunotherapies. The company's research centers on modulating regulatory T cells (Tregs) to overcome immune suppression within the tumor microenvironment. By leveraging insights from leading researchers at Memorial Sloan Kettering Cancer Center, Neeyan aims to create targeted therapies that selectively inhibit Treg activity while sparing effector T cell function. Their approach seeks to provide more effective and less toxic treatments for patients with various solid tumors. The company is backed by prominent life science investors and is headquartered in California.